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INTRODUCTION
Obstructive sleep apnea syndrome (OSAS) has been
reported to not only aggravate impaired glucose
tolerance by inducing insulin resistance through
nocturnal hypoxemia and enhanced sympathetic tonus,
but also serves as an independent risk factor of
cardiovascular disorders and hypertension (1). Wilcox
et al.(2) proposed Syndrome Z as a pathological state
with cumulative risk factors, and Reaven et al. proposed
that, when sleep apnea is added to Syndrome X, this
situation corresponds to the current metabolic syn-
drome. It has been reported that OSAS is a cause of
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an increase in the production of vascular adhesion
molecules (intercellular adhesion molecule -1; ICAM-1,
vascular cell adhesionmolecule 1 ; VCAM-1, and L-
selectin), inflammatory cytokine(interleukin-8 ; IL-8),
and monocyte chemoattractant protein -1, which serves
as an important risk factor of cardiovascular disease,
and nasal continuous positive airway pressure(CPAP)
treatment decreases the level of vascular adhesion
molecules and inflammatory cytokine in the treat-
ment of OSAS.
Angiotensin II receptor antagonists (ARBs) have
recently been suggested to inhibit the progression
of vascular inflammation in arteriosclerotic lesions,
and inhibit monocyte/macrophage infiltration by
supressing an increase in vascular ICAM-1 expression
(3, 4). However, only a few studies have focused
on the issue of whether ARB improves vascular in-
flammation and the progression of atherosclerosis
associated with OSAS. In the present study, we
examined ARB-induced changes in the levels of
adhesion molecules and inflammatory cytokine to
investigate whether OSAS-associated risks, such as
arteriosclerotic disease, can be reduced without the
use of nasal CPAP, which is difficult in continuous
treatment.
METHODS
1) Subjects
The subjects were 30 patients with ischemic heart
disease (IHD) who had undergone coronary angi-
ography (16 men and 14 women with a mean age of
62.7±10.8 years) and were confirmed to have sig-
nificant stenosis of the coronary artery. Patients with
a medical history of myocardial infarction, heart failure,
and renal failure (serum creatinine level＞2.5 mg/dl),
and patients with many branch lesions of the coronary
artery, a left ventricular ejection fraction of less than
50%, and diabetic and hypertensive patients were
excluded. For the diagnosis of IHD, patients with
significant stenosis of the coronary artery by 50% or
higher on coronary angiography were selected.
Patients that had been treated with angiotensin II
receptor antagonists, angiotensin converting enzyme
inhibitors, statin, and autonomic modifiers were
excluded from the study. The IHD groupwas divided
into two groups ; i.e., patients with OSAS [IHD
(AHI40) group] and those without [IHD(AHI<40)
group].
The control group was comprised of 20 healthy
subjects without a sleep apnea attack (N group, 12
men and 8 women with a mean age of 60.4±8.6 years).
These subjects without a past medical history of
circulatory disorders who exhibited typical normal
physical findings, a normal standard 12-lead elec-
trocardiogram, and chest X-ray radiogram without a
sleep apnea attack were investigated.
These studies were approved by the Tokushima
University Ethics Committee (No. 133), and the pa-
tients gave written, informed consent prior to their
participation.
2) Sleep apnea test
The sleep apnea test was performed 1 week
before coronary arteriography. Respiratory information
during sleep was collected using a portable sleep
polygraph (Sleep Tester LT-200, Fukuda Denshi Co.,
Ltd., Tokyo, Japan). Oronasal airflow measured by
the thermocouple method, tracheal sound by the
microphone method, chest respiration by the air-
bag method, and percutaneous arterial oxygen
saturation by the 2-wavelength pulse waveform
method were continuously recorded during night
sleep.
A personal computer (Windows XP) and sleep apnea
measurement software (SAS -100, FukudaDensh Co.,
Ltd.) were used for the measurements. The apnea-
hypopnea index (AHI), percutaneous arterial oxygen
saturation, and the duration of apnea weremeasured.
A respiratory volume of 1/4 or less was regarded as
hypopnea, and the apnea-hypopnea thresholdwas set
to 10 seconds or longer. The full-polygraph is fun-
damentally indispensable for diagnosis of OSAS, the
diagnostic criterion for SAS is 5 times or more AHI
per hour. But we adopted more than 40 times of AHI
as criteria of sleep apnea in the present study because
of a portable sleep polygraph.
3) Measurement of high-sensitivity C reactive protein
(hs-CRP), ICAM-1, and interleukin 6 (IL-6)
Hs-CRP, ICAM-1, and IL-6 were measured one
time at the start of this study in the N group, and twise
before and 24 weeks after valsartan administration
in the IHD group. We used a high-sensitivity CRP
assay (N-Latex CRP II, Dade Behring, DE, USA), by
which system the lowest detection limit is 0.05 mg/
dl, for the measurement of hs-CRP. The concentra-
tions of ICAM-1 and IL-6 in the serum were meas-
ured by enzyme-linked immunosorbent assey
(ELISA) and chemiluminescnce enzyme immu-
noassay (CLEIA) methods, respectively.
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4) Administration of valsartan, an angiotensin II
receptor antagonist (ARB)
After coronary arteriography, valsartan (80 - 160mg/
day) were orally administered to all patients in the
IHD group. Hs-CRP, ICAM-1, and IL-6 were measured
for 24 weeks afterward. Percutaneous coronary an-
gioplasty and/or bypass surgery were performed
24 weeks after valsartan administration. Patients with
severe stenosis and unstable anginawho needed these
treatments before 24 weeks were excluded from this
study.
5) Statistical analysis
All values are expressed as the mean±standard
deviation (SD), and statistical analyses were performed
using StatView 5.0 (SAS Institute Inc. Cary, NC, USA).
A comparison among each groupwas performed using
ANOVA, while the correlation between the two groups
was evaluated using a single regression analysis. In
addition, the influence of the respective factors on
AHI was evaluated by calculating the 95% confidence
intervals in a logistic regression model using a multi-
variate analysis. P-values less than 0.05were considered
significant.
RESULTS
1) OSAS in IHD group
Fig. 1 shows a portable sleep polygram of a patient
with OSAS in whom significant stenosis was detected
by coronary arteriography. Oronasal respiration was
decreased, but no decrease the thoracic movement
was noted, and percutaneous oxygen saturation was
decreased.TheAHIwas42.2, and, as a result, this patient
was diagnosed with OSAS. The body mass index
was 24.5, hs-CRP, ICAM-1 and IL-6 were 0.369 mg/dl,
661 ng/ml, and 7.71 pg/ml, respectively
Fig. 2 shows the frequency of complications with
OSAS in the IHD group. OSAS was detected in 9 of
the 30 patients (30%) in the IHD group.
2) Comparison of hs-CRP, ICAM-1 and IL-6 before
and after valsartan administration between N and IHD
groups
Figs. 3 shows comparisons of hs-CRP (panel a),
ICAM-1 (panel b), and IL-6 (panel c) before and after
valsartan administration between the N, IHD(AHI
40), and IHD(AHI<40) groups. The hs-CRP, ICAM-1,
and IL-6 levels before valsartan administration were
significantly higher in the IHD group than in the
N group (p<0.01). Moreover, hs-CRP, ICAM-1, and
IL-6 were significantly higher in the IHD (AHI40)
group than in the IHD (AHI<40) group (p<0.01)
before valsartan administration.
After the valsartan administration, valsartan sig-
nificantly decreased hs-CRP, ICAM-1, and IL-6 in the
IHD group, especially the (AHI40) group. The
significant differences among the IHD(AHI40),
IHD(AHI<40), and N groups disappeared after the
administration of valsartan.
3) Logistic multivariate analysis of humoral factors
using AHI index
Table 1 shows a logistic multivariate analysis of the
humoral factors (hs-CRP, ICAM-1, and IL-6) using
AHI index. The hs-CRP (relative risk=1.642, p=
0.038), ICAM-1(relative risk=1.560, p=0.042), and
IL-6 (relative risk=1.301, p=0.048) values were
individually independent risk factors for the
severity of OSAS in the IHD group.
Fig. 1．Portable sleep polygram of a patient with OSAS in whom
significant stenosis was detected on coronary arteriography.
SpO2, percutaneous arterial oxygen saturation; BMI, body mass
index ; hs-CRP, high sensivity C reactive protain ; ICAM-1, in-
tercellular adhesion molecule-1 ; IL-6, interleukin-6
Fig. 2．Frequency of complications with OSAS in the IHD
group
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DISCUSSION
The levels of inflammatory marker (hs-CRP), the
vascular adhesion molecule (ICAM-1), and the in-
flammatory cytokine (IL-6) were increased in OSAS
patients with a coronary arterial lesion, suggesting
that the risk of cardiovascular disorder is increased
in OSAS patients compared to patients without OSAS.
However, the findings indicate that valsartan, an
angiotensin II receptor antagonist, decreased hs-CRP,
ICAM-1, and IL-6 levels, suggesting that rennin-
angiotensin pathways are involved in the development
of atherosclerosis in OSAS. The results also suggest
that angiotensin II receptor antagonistsmay decrease
the risk of arteriosclerosis and cerebrovascular and
cardiovascular in OSAS patients with a coronary
arterial lesion (secondary prevention).
1) Relation between OSAS and arteriosclerosis
A relation between OSAS and the progression of
arteriosclerosis, especially an associationwith an increase
in the risk of cardiovascular and cerebrovascular
morbidity, has been reported (5). Intermittent hypoxemia
in sleep apnea alters autonomic nervous activation,
neuroendocrine function, releases potent proin-
flammatory mediators (TNF-a, interleukin-6), fibrinogen,
plasminogen activator inhibitor, and reduces fibrinolytic
activity (6 -11). Moreover, leukocyte adhesion and
accumulation on endothelial cells are common in
patients with OSAS (9). Hein et al. also reported that
hs-CRP, IL-6, IL-8, IL-10, TNF-a, ICAM-1, VCAM-1,
L-Selectin, and insulin resistance are increased in
OSAS patients (12). Consistent with previous reports,
the levels of hs-CRP, ICAM-1 and IL-6 were also
found to be significantly increased in OSAS patients
with a coronary arterial lesion compared to patients
with a coronary arterial lesion alone in this study.
Regarding the increases in these humoral factors,
many of the factors are fat tissue-derived, physi-
ologically active substances, and this is more likely
due to obesity thanOSAS (13, 14). However, the ICAM-1
gene is associated with a significant reduction in
objective sleepiness in obese patients withOSAS (15).
Moreover, obesity is a risk factor for high serum
CRP levels in patients with sleep-disordered breathing
(15).
Many reports on the severity of OSAS indicate
the association of humoral factors with OSAS.
Shamsuzzaman et al.reported that CRP levels, a
marker of inflammation and cardiovascular risk,
were independent of the severity of OSAS (16). In
addition, the increased levels of adhesion mole-
Table 1. Logistic multivariate analysis of the humoral factors
(hs-CRP, ICAM-1,and IL-6) using AHI index
Relative risk 95% CI p
hs-CRP
ICAM-1
IL-6
1.642
1.560
1.301
0.836～2.851
0.798～2.248
0.628～1.630
0.038
0.042
0.063
hs-CRP, high sensivity C reactive protain ;
ICAM-1, intercellular adhesion molecule-1 ; IL-6, interleukin-6 ;
AHI index, apnea-hypopnea index.
Fig. 3．Comparisons of hs-CRP (panel a), ICAM-1 (panel b), and
IL-6 (panel c) before and after valsartan administration between
the N, IHD(AHI40), and IHD(AHI<40) groups.
hs-CRP, high sensivity C reactive protain ; ICAM-1, intercellular
adhesion molecule-1 ; IL-6, interleukin-6 ; IHD, ischemic heart
disease ; AHI, apnea-hypopnea index.
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cules were correlated with the AHI and oxygen
desaturation index, but not with the severity of hy-
poxemia or mediators (17).
Yokoe et al. and Chin et al. reported that CRP and
IL-6 are important risk factors of arteriosclerosis and
coronary arterial disorders, and that these factors
were significantly decreased by nasal CPAP treatment
and were related to the prognosis of OSAS (18, 19).
Harsch et al. also reported that nasal CPAP de-
creased IL-6 and ICAM-1 levels and increased
insulin sensitivity (20). In the present study, an as-
sociation between hs-CRP and ICAM-1 levels and
the severity of OSAS was also noted in a multivari-
ate analysis, suggesting that hs-CRP and ICAM-1
are also related to the severity of OSAS, and that
this is not due to obesity alone.
2) Effect of valsartan on OSAS
The use of adhesion molecules as a prognostic
marker of coronary arterial disease has been reported.
Blankenberg et al.(21) reported that the blood levels
of the vascular adhesion molecule (VCAM-1), the cell
adhesion molecule (ICAM-1), and E-secretion were
correlated with a risk of cardiovascular death, and
the combination of these with the CRP level was useful
for predicting survival (21). In another study (22), blood
IL-6 levels were reported to be a strong independent
predictive factor of high mortality in patients with
unstable coronary arterial disease, and was useful for
the determination for early invasive therapy indication.
Therefore, it is necessary to investigate the
usefulness of therapeutic methods that inhibit these
inflammatory markers in OSAS patients with coronary
arterial lesions. Valsartan, an angiotensin II receptor
antagonist, inhibits the production of inflammatory
cytokines, MCP-1, IL-6, IL-1β, and TNF-α, and inhibits
the formation of new tunica intima and the migration
of vascular smooth muscle cells, in addition to its
hypotensive effect (23). Valsartan was also reported
to prevent monocyte/macrophage infiltration and the
excessive expression of the adhesion molecules,
Plasminogen activator inhibitor-1 (PAI-1), and fibronectin
(24). Moreove, valsartan has antioxidative action, and
prevents atherosclerosis by inhibiting the oxidation
of low-density lipoproteins (LDL) and decreases free
radical levels (25, 26).
A number of reports of the usefulness of an-
giotensin II receptor antagonists for coronary
arterial diseases have appeared, and such drugs
are recommended for cases without contraindica-
tions. In the present study, valsartan improved in-
flammatory markers, adhesion molecules, and cy-
tokines in patients with concomitant coronary arterial
lesions and OSAS, suggesting that it might be useful
for the secondary prevention of ischemic heart disease.
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